Colorectal cancer in patients with inflammatory bowel disease: The true impact of the risk

Digestive Diseases

Volumn 33, Issue 1, 2014, Pages 52-57

  Herszényi, László ^a   Barabás, Loránd ^a   Miheller, Pál ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Colorectal cancer; Crohn's disease; Inflammatory bowel disease; Risk factors; Surveillance; Ulcerative colitis

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RISK; CHROMOENDOSCOPY; CHROMOSOMAL INSTABILITY; CHRONIC INFLAMMATION; COLITIS; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; FAMILY HISTORY; HUMAN; INFLAMMATORY BOWEL DISEASE; ONSET AGE; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; ULCERATIVE COLITIS; CARCINOGENESIS; COLORECTAL TUMOR; COMPLICATION; GENETICS; INFLAMMATION; PATHOLOGY; RISK FACTOR;

CARCINOGENESIS; COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 84919786953     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000368447     Document Type: Review

References (64)

1. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
2. Kucharzik T, Maaser C, Lugering A, Lügering A, Kagnoff M, Mayer L, Targan S, Domschke W: Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006; 12: 1068-1083.
3. Abraham C, Medzhitov R: Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011; 140: 1729-1737.
4. Lakatos G, Hritz I, Varga MZ, Juhász M, Miheller P, Cierny G, Tulassay Z, Herszényi L: The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig Dis 2012; 30: 289-295.
5. Crohn B, Rosenberg H: The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925; 170: 220-228.
6. Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(suppl 2):1-5.
7. Lakatos PL, Lakatos L: Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008; 14: 3937-3947.
8. Lukas M: Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 2010; 28: 619-624.
9. Herszényi L, Lakatos G, Hritz I, Varga MZ, Cierny G, Tulassay Z: The role of inflammation and proteinases in tumor progression. Dig Dis 2012; 30: 249-254.
10. Rogler G: Chronic ulcerative colitis and colorectal cancer. Cancer Lett 2014; 345: 235-241.
11. Velayos FS, Ullman TA: Looking forward to understanding and reducing colorectal cancer risk in inflammatory bowel disease. Gastroenterology 2013; 145: 47-49.
12. Mehta SJ, Silver AR, Lindsay JO: Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 77-79.
13. Seidelin JB, Coskunm M, Nielsen OH: Mucosal healing in ulcerative colitis: pathophysiology and pharmacology. Adv Clin Chem 2013; 59: 101-123.
14. Herszényi L, Miheller P, Tulassay Z: Carcinogenesis in inflammatory bowel disease. Dig Dis 2007; 25: 267-269.
15. Fujiwara I, Yashiro M, Kubo N, Maeda K, Hirakawa K: Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis Colon Rectum 2008; 51: 1387-1394.
16. Scarpa M, Castagliuolo I, Castoro C, Pozza A, Scarpa M, Kotsafti A, Angriman I: Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. World J Gastroenterol 2014; 20: 6774-6785.
17. Allen PB, Kamm MA, De Cruz P, Desmond PV: Dysplastic lesions in ulcerative colitis: changing paradigms. Inflamm Bowel Dis 2010; 16: 1978-1983.
18. Rutter MD, Riddell RH: Colorectal dysplasia in inflammatory bowel disease: a clinicopathologic perspective. Clin Gastroenterol Hepatol 2014; 12: 359-367.
19. Redston MS, Papadopoulos N, Caldas C, Kinzler KW, Kern SE: Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 1995; 108: 323-392.
20. Yoshimi K, Tanaka T, Serikawa T, Kuramoto T: Tumor suppressor APC protein is essential in mucosal repair from colonic inflammation through angiogenesis. Am J Pathol 2013; 182: 1263-1274.
21. Lashner BA, Bauer WM, Rybicki LA, Goldblum JR: Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. Am J Gastroenterol 2003; 98: 1423-1427.
22. Goretsky T, Dirisina R, Sinh P, Mittal N, Managlia E, Williams DB, Posca D, Ryu H, Katzman RB, Barrett TA: p53 mediates TNFinduced epithelial cell apoptosis in IBD. Am J Pathol 2012; 181: 1306-1315.
23. Kim TO, Park J, Kang MJ, Lee SH, Jee SR, Ryu DY, Yang K, Yi JM: DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis. Int J Mol Med 2013; 31: 1255-1261.
24. Azuara D, Rodriguez-Moranta F, de Oca J, Sanjuan X, Guardiola J, Lobaton T, Wang A, Boadas J, Piqueras M, Monfort D, Galter S, Esteller M, Moreno V, Capellá G: Novel methylation panel for the early detection of neoplasia in high risk ulcerative colitis and Crohn's colitis patients. Inflamm Bowel Dis 2013; 19: 165-173.
25. Azer SA: Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Eur J Gastroenterol Hepatol 2013; 25: 271-281.
26. Papadia C, Louwagie J, Del Rio P, Grooteclaes M, Coruzzi A, Montana C, Novelli M, Bordi C, de' Angelis GL, Bassett P, Bigley J, Warren B, Atkin W, Forbes A: FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis-associated colorectal neoplasia. Inflamm Bowel Dis 2014; 20: 271-277.
27. Ryan BM, Wolff RK, Valeri N, Khan M, Robinson D, Paone A, Bowman ED, Lundgreen A, Caan B, Potter J, Brown D, Croce C, Slattery ML, Harris CC: An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiol 2014, Epub ahead of print.
28. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S; IBD Section of the British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
29. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G: Second European evidence- based consensus on the diagnosis and management of ulcerative colitis. Part 1. Definitions and diagnosis. J Crohns Colitis 2012; 6: 965-990.
30. Eaden JA, Abrams KR, Mayberry JF: The true risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gastroenterology 2001; 48: 526-535.
31. Jess T, Gamborg M, Matzen P, Munkholm P, Sörensen TI: Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population based cohort studies. Am J Gastroenterol 2005; 100: 2724-2729.
32. Canavan C, Abrams KR, Mayberry J: Metaanalysis: colorectal cancer and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097-1104.
33. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP: The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007; 50: 839-855.
34. Dyson JK, Rutter MD: Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol 2012; 18: 3839-3848.
35. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL: Risk factors of ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 205-211.
36. Andersen NN, Jess T: Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol 2013; 19: 7561-7568.
37. Mooiweer E, Baars JE, Lutgens MW, Vleggaar F, van Oijen M, Siersema PD, Kuipers EJ, van der Woude CJ, Oldenburg B: Disease severity does not affect the interval between IBD diagnosis and the development of CRC: results from two large, Dutch case series. J Crohns Colitis 2012; 6: 435-440.
38. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A: Thirtyyear analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038.
39. Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J: Decreasing time trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136: 1561-1567.
40. Winther KV, Jess T, Langholz E, Munkholm P, Binder V: Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 1077-1095.
41. Jess T, Winther KV, Munkholm P, Langholz E, Binder V: Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population- based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004; 19: 287-293.
42. Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Kiss LS, Lakatos L: Risk of colorectal cancer and small bowel adenocarcinoma in Crohn's disease: a population-based study from western Hungary 1977-2008. J Crohns Colitis 2011; 5: 122-128.
43. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B: Declining risk of colorectal carcinoma in inflammatory bowel disease: an updated metaanalysis of population based cohort studies. Inflamm Bowel Dis 2013; 19: 789-799.
44. Peyrin-Biroulet L, Lepage C, Jooste V, Guéant JL, Faivre J, Bouvier AM: Colorectal cancer in inflammatory bowel disease a populationbased study (1976-2008). Inflamm Bowel Dis 2012; 18: 2247-2251.
45. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Fléjou JF, Carrat F; CESAME Study Group: Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013; 145: 166-175.
46. Baars JE, Kuipers EJ, van Haastert M, Nicolaï JJ, Poen AC, van der Woude CJ: Age at diagnosis of inflammatory bowel disease early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol 2012; 47: 1308-1322.
47. Wang R, Leong RW: Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol 2014; 20: 8783-8789.
48. Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group: Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014; 63: 1416-1423.
49. Wanders LK, Dekker E, Pullens B, Bassett P, Travis SP, East JE: Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 756-764.
50. Derikx LA, Kievit W, Drenth JP, de Jong DJ, Ponsioen CY, Oldenburg B, van der Meulende Jong AE, Dijkstra G, Grubben MJ, van Laarhoven CJ, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis: Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease. Gastroenterology 2014; 146: 119-128.
51. Grivennikov SI: Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013; 35: 229-244.
52. Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K; Japanese Society for Cancer of the Colon and Rectum: Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic cancer; a nationwide Japanese study. Inflamm Bowel Dis 2011; 17: 802-808.
53. Jensen AB, Larsen M, Gislum M, Skriver MV, Jepsen P, Nörgaard B, Sörensen HT: Survival after colorectal cancer in patients with ulcerative colitis: nationwide population-based Danish study. Am J Gastroenterol 2006; 101: 1283-1287.
54. Adams SV, Ahnen DJ, Baron JA, Campbell PT, Gallinger S, Grady WM, LeMarchand L, Lindor NM, Potter JD, Newcomb PA: Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry. World J Gastroenterol 2013; 19: 3241-3248.
55. Bressenot A, Cahn V, Danese S, Peyrin-Biroulet L: Microscopic features of colorectal neoplasia in inflammatory bowel diseases. World J Gastroenterol 2014; 20: 3164-3172.
56. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO: Second European Crohn's and Colitis Organisation: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 3. Special situations. J Crohns Colitis 2013; 7: 1-33.
57. Lutgens M, van Oijen M, Mooiweer E, Valk MV, Vleggaar F, Siersema P, Oldenburg B: A risk-profiling approach for surveillance of inflammatory bowel disease-colorectal carcinoma is more cost-effective: a comparative costeffectiveness analysis between international guidelines. Gastrointest Endosc 2014, Epub ahead of print.
58. Lutgens M, Vermeire S, Van Oijen M, Vleggaar F, Siersema P, van Assche G, Rutgeerts P, Oldenburg B: A rule of determining risk of colorectal cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2014, Epub ahead of print.
59. Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP: Colonoscopy is associated with a reduced risk of colorectal cancer and mortality in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2014, Epub ahead of print.
60. Soetikno R, Subramanian V, Kaltenbach T, Rouse RV, Sanduleanu S, Suzuki N, Tanaka S, McQuaid K: The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology 2013; 144: 1349-1352.
61. Naymagon S, Marion JF: Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement. Gastrointest Endosc Clin N Am 2013; 23: 679-694.
62. Rutter MD, Riddell RH: Colorectal neoplasia in inflammatory bowel disease: a clinicopathologic perspective. Clin Gastroenterol Hepatol 2014; 12: 359-367.
63. Kwah J, Farraye F: Current and future status for evaluation of dysplasia and carcinoma in IBD. Curr Treat Options Gastroenterol 2014; 12: 90-102.
64. Conelly TM, Koltun WA: The cancer 'fear' in IBD patients: is it still real? J Gastrointest Surg 2014; 18: 213-218.